Simple Science

Cutting edge science explained simply

# Biology # Bioinformatics

Group B Streptococcus: The Hidden Threat

Understand Group B Streptococcus and its rising infections.

Veronica Kovacec, Sabrina Di Gregorio, Mario Pajon, Uzma Basit Khan, Tomas Poklepovich, Josefina Campos, Chiara Crestani, Stephen D. Bentley, Dorota Jamrozy, Marta Mollerach, Laura Bonofiglio

― 6 min read


GBS: A Growing Danger GBS: A Growing Danger rising, impacting newborns and adults. Group B Streptococcus infections
Table of Contents

Group B Streptococcus, often referred to as GBS or Streptococcus agalactiae, is a type of bacteria that can live peacefully in the human body. It is often found in the intestines and the urinary tract without causing harm. However, this harmless tenant can turn into a troublemaker, especially for newborns and certain adults.

GBS is a significant concern because it is the leading cause of serious infections in newborns, including sepsis and meningitis. It can also cause pneumonia in infants. Most new parents would prefer to deal with diaper disasters rather than bacterial infections, so it's crucial to understand how GBS operates.

Increased GBS Infections

In recent years, GBS infections have been on the rise, not just in infants but also in older adults and those with health issues. It seems that GBS is getting a bit too comfortable in its role as a troublemaker. Certain factors, like being elderly or having conditions such as diabetes or cancer, can increase the risk of GBS-related infections in adults.

Treatment Options

The primary medication for treating GBS infections is penicillin. It's like the go-to superhero in the world of antibiotics. If penicillin is not an option-because some people are allergic-doctors might turn to other antibiotics like macrolides or lincosamides. For more stubborn cases where those do not work, there's vancomycin, but it’s saved for special occasions, kind of like the reserve champagne for New Year’s Eve.

Rise of Resistance

In an alarming twist, bacteria can develop resistance to these antibiotics, making it harder to treat infections. Over the years, GBS has become resistant to several types of antibiotics. It's like the bacteria are throwing a party and not letting anyone in. This growing resistance is closely linked to the spread of more dangerous GBS strains, called multidrug-resistant clones.

Vaccines in Development

Currently, there are no approved vaccines for preventing GBS infections, much to the disappointment of health professionals everywhere. However, researchers are hard at work developing vaccines that target specific GBS types. The success of these vaccines will depend on how well they can cover the different types circulating in any given area.

To get a better grip on GBS diversity, an international group called Juno has been formed. They are studying GBS from around the world to understand its variations and how this bacteria behaves.

Prophages: The Bacterial Sidekicks

Inside GBS, there are entities known as prophages. These are essentially bits of DNA that can help bacteria evolve. They can add new genetic traits, which may help GBS survive better and become more virulent. It is said that up to 20% of some bacterial genomes is made up of these little sidekicks.

Many pathogenic bacteria carry more of these prophage-related genes, which has also been noted for GBS. In fact, studies suggest that some of these prophages may come from animals and could be linked to the rise of certain GBS strains that cause illnesses in infants and adults.

The Study of GBS in Argentina

In a recent endeavor, researchers investigated the presence of prophages in GBS isolated from a variety of sources in Argentina. They collected samples from different health centers across the country and analyzed the genetic diversity of GBS strains.

Sample Collections

Over the course of a national study, they gathered GBS samples from patients with invasive infections, urinary infections, and even pregnant women. They ended up with a dataset of 450 isolates, focusing on 365 of them for detailed analysis.

This comprehensive study included samples from infants, children, and adults, each contributing to a better understanding of how GBS behaves in varied situations.

Genomic Analysis

To study the bacteria further, researchers conducted whole genome sequencing. They used specialized software and databases to analyze the genetic makeup of the GBS strains. This provided a detailed overview of the core genes and allowed them to build a family tree of the bacteria.

Researchers also focused on Capsular Types, which are important in identifying GBS strains. This classification helps in understanding the potential for disease caused by different types of GBS.

Findings on Capsular Types and Lineage

The findings revealed several interesting patterns. Certain capsular types were significantly associated with specific GBS lineages, with CC23 and CC12 being the most dominant in Argentina. These lineages were similar to GBS strains found in other parts of the world, showing that GBS doesn't discriminate based on geography-it’s all about survival.

Interestingly, some strains emerged that were classified as non-typeable, meaning they couldn’t be easily grouped into known types. This raises questions about their potential Virulence and the effectiveness of vaccines targeting specific types.

The Role of Prophages

In their analysis, the researchers found a total of 454 prophages across the GBS genomes. Most strains had one or two prophages, while some carried up to four. The association between prophage presence and GBS lineages was also noteworthy, suggesting that certain prophages might be more prevalent in specific lineages.

This information could potentially guide future vaccine development and give insights into how GBS strains evolve and adapt.

Virulence Determinants and Antibiotic Resistance

The researchers also investigated the virulence factors of GBS, identifying several genes that contribute to its ability to cause disease. Interestingly, antibiotic resistance determinants were found in a significant number of the isolates. About 90% of the genomes harbored genes that confer resistance to at least one antibiotic class.

This highlights a serious public health concern. With more strains developing resistance, understanding the genetic basis behind this resistance becomes urgent.

Multiple Antibiotic Resistance

Furthermore, some strains harbored resistance to multiple classes of antibiotics. This multidrug resistance is alarming and emphasizes the need for constant monitoring of GBS strains circulating in the population.

Conclusion: The Need for Ongoing Surveillance

The analysis of GBS in Argentina contributes valuable information to the understanding of this bacterium's population structure. It underscores the importance of ongoing research to monitor GBS infections, especially as antibiotic resistance continues to rise.

With a better grasp of GBS behavior, virulence factors, and resistance patterns, researchers and healthcare professionals can work together to develop effective prevention strategies, including vaccines that could save lives.

In the end, while GBS may seem like just another bacteria, its ability to adapt and cause serious infections makes it a key player in the world of infectious diseases. So, stay informed, because knowledge is power-especially when it comes to keeping your little ones safe and healthy!

Original Source

Title: Genomic Characterisation of Group B Streptococcus from Argentina: Insights into Prophage Diversity, Virulence Factors and Antibiotic Resistance Genes

Abstract: Group B Streptococcus (GBS) is a commensal bacterium that can cause severe infections in infants and adults with comorbidities. Resistance and reduced susceptibility to antibiotics is continually on the rise, and vaccines remain in-development. Prophages have been reported to contribute to GBS evolution and pathogenicity. However, no studies are available to date on prophage contribution to the epidemiology of GBS isolates from humans in South America. In the context of an Argentinian multicentric study, we had previously phenotypically characterised 365 human GBS isolates from invasive disease, urinary infections and maternal colonisation. These isolates had been whole genome sequenced and their prophage presence bioinformatically determined. In this study, we genomically characterised the isolates and analysed the prophage content in the context of the epidemiological data. The phylogenetic analysis of the 365 genomes with 103 GBS from public databases revealed that Argentinian GBS were related to isolates from around the world. The most prevalent lineages, independently of the isolate source, were CC23/Ia and CC12/Ib. Genes encoding virulence factors involved in immune response evasion, tissue damage and adherence to host tissues and invasion were found in all of the genomes in accordance with previously described lineage distribution. According to the prevalent capsular types and the distribution of specific virulence factors in Argentinian GBS, over 95% coverage would be expected from the vaccines currently under development. Antibiotic resistance determinants (ARDs) to at least one antibiotic class were found in 90% of the genomes, including novel mutations in pbp2x, while more than 15% carried ARDs to 3 or more classes. GBS collected from urinary infections carried a significantly higher proportion of ARDs to multiple antibiotic classes than the rest of the isolates. A total of 454 prophages were found among the 468 genomes analysed, which were classified into 23 prophage types. Prophage presence exhibited variations based on GBS clonal complex and capsular type. A possible association between an increased GBS pathogenicity and the carriage of prophages with integrase type GBSInt8 and/or the presence of genes that encode the Phox Homology domain has been observed. The highest prevalence of prophages per genome was found in lineages CC17/III and CC19/III, while the lowest amount was observed in CC12/Ib. Overall, the highest density of prophages, virulence factors and ARDs determinants was found in CC19 isolates, mostly of capsular type III, independently of the isolates source. This is the first analysis of the human-associated GBS population in South America based on whole genome sequencing data, which will make a significant contribution to future studies on the global GBS population structure. Data summarySupplementary results and figures can be found in Supplementary Material 1. Supplementary tables can be found in Supplementary Material 2. All datasets analysed in this study are detailed in the Supplementary Materials. Metadata about the genomes analysed can be found in the microreact project created for this study: https://microreact.org/project/gbs-pangenomic-analysis. Impact statementIn Latin America studies on the epidemiology of Group B Streptococcus (GBS) are scarce, especially those describing clonal complex and serotype distribution, and the role of prophages in GBS epidemiology has not been studied. This article addresses the first genomic characterisation of the human-isolated GBS population in Latin America based on whole genome sequencing data, with special focus on the analysis of prophage content. We determine the clonal complex and serotype distribution of 365 GBS isolates collected from clinical samples in an Argentinian multicenter study and analyse the presence of prophages and virulence and antibiotic resistance determinants in the context of the epidemiological data. Through these analyses, we were able to determine how GBS population structure in Argentina differs from other parts of the world and to predict the potential coverage of the in-development GBS vaccines. We also found a possible association between the carriage of certain types of prophages and an increased GBS pathogenicity. In the context of increased global efforts to develop new strategies to prevent GBS infections through vaccine development, this study makes a significant contribution to our understanding of the global GBS population structure.

Authors: Veronica Kovacec, Sabrina Di Gregorio, Mario Pajon, Uzma Basit Khan, Tomas Poklepovich, Josefina Campos, Chiara Crestani, Stephen D. Bentley, Dorota Jamrozy, Marta Mollerach, Laura Bonofiglio

Last Update: Dec 23, 2024

Language: English

Source URL: https://www.biorxiv.org/content/10.1101/2024.12.20.629649

Source PDF: https://www.biorxiv.org/content/10.1101/2024.12.20.629649.full.pdf

Licence: https://creativecommons.org/licenses/by/4.0/

Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.

Thank you to biorxiv for use of its open access interoperability.

Similar Articles